1. Home
  2. CCCC

as of 01-23-2026 3:40pm EST

$2.15
$0.04
-1.61%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Founded: 2015 Country:
United States
United States
Employees: 110 City: WATERTOWN
Market Cap: 208.4M IPO Year: 2020
Target Price: $7.25 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.67 EPS Growth: N/A
52 Week Low/High: $1.08 - $3.84 Next Earning Date: 02-26-2026
Revenue: $30,108,000 Revenue Growth: -10.57%
Revenue Growth (this year): -10.68% Revenue Growth (next year): -31.54%

AI-Powered CCCC Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 0.00%
0.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of C4 Therapeutics Inc. (CCCC)

REYNO LEONARD

Chief Medical Officer

Sell
CCCC Jan 16, 2026

Avg Cost/Share

$2.22

Shares

10,000

Total Value

$22,200.00

Owned After

156,382

SEC Form 4

Share on Social Networks: